161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Reports First Quarter 2026 Financial Results and Business Highlights
Annual Report to Security Holders
Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Material disclosure
U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Q1
FY 2024
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence